The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Materials and Methods: The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m2 docetaxel D1, 75 mg/m2 cisplatin D1, 1000 mg/m2 5-FU D1-4, and subsequently received concurrent chemoradiation therapy. Results: Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6∼39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3∼4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105). Conclusion: TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity. (Cancer Res Treat. 2007;39:93-98)
Abstract
Purpose: This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Materials and Methods: The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m2 docetaxel D1, 75 mg/m2 cisplatin D1, 1000 mg/m2 5-FU D1-4, and subsequently received concurrent chemoradiation therapy. Results: Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6∼39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3∼4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105). Conclusion: TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity. (Cancer Res Treat. 2007;39:93-98)
참고문헌 (25)
- Forastiere A, "Head and neck cancer", 345, pp.1890~1900 (2001)
- Jemal A, "Cancer statistics, 2006", 56, pp.106~130 (2006)
- Lefebvre JL, "Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group", 88, pp.890~899 (1996)
- Guadagnolo BA, "Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer", 28, pp.371~378 (2005)
- Pignon JP, "Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data", 355, pp.949~955 (2000)
- Janinis J, "Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced", recurrent head and neck cancer: a phase II feasibility study, 2000, pp.23, 128~131
- Hanauske A, "an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5", pp.533~7
- Lee JH, "Docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinomas of the head and neck", 35, pp.261~266 (2003)
- Hitt R, "Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial", 13, pp.1665~1673 (2002)
- Hitt R, "Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer", 23, pp.8636~8645 (2005)
- Diaz JF, "Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere", pp.2747~55
- Haldar S, "Bcl2 is the guardian of microtubule integrity", 57, pp.229~233 (1997)
- Posner MR, "Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck", 19, pp.1096~1104 (2001)
- Haddad R, "Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience", 97, pp.412~418 (2003)
- Colevas AD, "Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I", II trial, 1998, pp.16, 1331~1339
- Colevas AD, "Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck", 17, pp.3503~3511 (1999)
- Colevas AD, "Phase I", II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN), 2002, pp.25, 153~159
- Posner MR, "Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach", 31, pp.778~785 (2004)
- Tae K, "Neoadjuvant chemotherapy followed by concurrent chemoradiation in locally advanced head and neck squamous cell carcinoma", 50, pp.327~334 (2007)
- Vokes EE, "Head and neck cancer", pp.501~ (2004), Seoul: McGraw-Hill
- Gomez H, "patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity", 16, pp.2352~2358 (1998)
- Lyman GH, "Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices", 21, pp.4524~4531 (2003)
- Dees EC, "A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer", 18, pp.521~529 (2000)
- Schild SE, "The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly", 21, pp.3201~3206 (2003)
- Choi YJ, "Induction chemotherapy of docetaxel and cisplatin for the elderly patients with squamous cell carcinoma of the head and neck", 39, pp.1~5 (2007)